Hannah Shen is passionate about developing novel therapies for diseases with a high unmet need. She joined Octant Bio as VP of Strategy to formulate corporate and R&D strategies to engineer impactful drugs for patients.

Prior to joining Octant, Hannah was VP of the Asset Acquisition team at BridgeBio, leading a tight-knit five-person team responsible for identifying, diligencing, and bringing in new therapies. She was involved in the creation of 15+ new programs and shaped the inception of BridgeBio X. Before then, Hannah was employee number 17 at software company Benchling, where she led initial efforts to develop marketing and business development strategy, leading to 8x revenue growth over the first 18 months and Benchling’s first two deals with top 5 pharma companies.

Hannah received her PhD in molecular biology from Harvard University, where she studied the neuronal basis of chemotaxis in C. elegans. Her work led to a co-first-author publication in Nature. She grew up in Taipei, Taiwan, and loves hiking, trying new foods, cats, and volleyball.

Papers

https://www.nature.com/articles/s41592-018-0233-6

https://www.nature.com/articles/nature11431

https://www.cell.com/cell/fulltext/S0092-8674(10)00672-0